Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms

被引：0
|
作者：
Orliaguet, Marie [1 ]
Boisrame, Sylvie [1 ]
Eveillard, Jean-Richard [2 ]
Pan-Petesch, Brigitte [2 ,3 ]
Couturier, Marie-Anne [2 ]
Rebiere, Vincent [2 ]
Guillerm, Gaelle [2 ]
Le Bousse-Kerdiles, Marie-Caroline [4 ,5 ]
Misery, Laurent [6 ]
Lippert, Eric [5 ,7 ,8 ]
Ianotto, Jean-Christophe [2 ,3 ,5 ]
机构：
[1] CHRU Brest, Dept Chirurg Orale, Brest, France
[2] CHRU Brest, Inst Cancerohematol, Serv Hematol Clin, Ave Foch, F-29609 Brest, France
[3] CHRU Brest, EA3878, Grp Etud Thromboses Bretagne Occidentale, GETBO, Brest, France
[4] Univ Paris XI, Inst Andre Lwoff, UMR S MD 1197, Villejuif, France
[5] France Intergrp Neoplasies Myeloproliferat FIM, Paris, France
[6] CHRU Brest, Serv Dermatol, Brest, France
[7] CHRU Brest, Lab Hematol, Brest, France
[8] Univ Brest, INSERM, UMR 1078, Brest, France
来源：
EJHAEM | 2020年 / 1卷 / 01期
关键词：
CHRONIC HEPATITIS-C; ALPHA-2B; TOXICITY;
D O I：
10.1002/jha2.15
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：350 / 352
页数：3
相关论文
共 50 条
  • [31] Treatment of Persistent Rhinovirus Infection With Pegylated Interferon α2a and Ribavirin in Patients With Hypogammaglobulinemia
    Ruuskanen, Olli
    Waris, Matti
    Kainulainen, Leena
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (12) : 1784 - 1786
  • [32] Treatment of hepatitis C in hemodialysis patients using pegylated interferon α-2a in Turkey
    Sukran Kose
    Alp Gurkan
    Fatih Akman
    Mehmet Kelesoglu
    Ufuk Uner
    Journal of Gastroenterology, 2009, 44 : 353 - 358
  • [33] Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialaEuro
    Eigentler, T. K.
    Gutzmer, R.
    Hauschild, A.
    Heinzerling, L.
    Schadendorf, D.
    Nashan, D.
    Hoelzle, E.
    Kiecker, F.
    Becker, J.
    Sunderkoeter, C.
    Moll, I.
    Richtig, E.
    Poenitzsch, I.
    Pehamberger, H.
    Kaufmann, R.
    Pfoehler, C.
    Vogt, T.
    Berking, C.
    Praxmarer, M.
    Garbe, C.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1625 - 1632
  • [34] Updated audit of the use of pegylated interferon in patients with myeloproliferative neoplasms. Are patients maintained on less frequent dosing than once weekly?
    Loughran, C.
    Wadelin, F.
    Fisken, R.
    Thompson, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 199 - 200
  • [35] Pegylated interferon α-2a versus standard interferon α-2a for treatment-naive dialysis patients with chronic hepatitis C:: a randomised study
    Liu, C-H
    Liang, C-C
    Lin, J-W
    Chen, S-I
    Tsai, H-B
    Chang, C-S
    Hung, P-H
    Kao, J-H
    Liu, C-J
    Lai, M-Y
    Chen, J-H
    Chen, P-J
    Kao, J-H
    Chen, D-S
    GUT, 2008, 57 (04) : 525 - 530
  • [36] Combination therapy with ruxolitinib and pegylated interferon alfa2a in newly diagnosed patients with polycythemia vera
    Sorensen, Anders Lindholm
    Skov, Vibe
    Kjaer, Lasse
    Bjorn, Mads Emil
    Eickhardt-Dalboge, Christina Schjellerup
    Larsen, Morten Kranker
    Nielsen, Claus H.
    Thomsen, Carsten
    Gjerdrum, Lise Mette Rahbek
    Knudsen, Trine Alma
    Ellervik, Christina
    Overgaard, Ulrik Malthe
    Andersen, Christen Lykkegaard
    Hasselbalch, Hans
    BLOOD ADVANCES, 2024, 8 (20) : 5416 - 5425
  • [37] A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naive patients with chronic hepatitis C
    Mangia, A
    Ricci, GL
    Persico, M
    Minerva, N
    Carretta, V
    Bacca, D
    Cela, M
    Piattelli, M
    Annese, M
    Maio, G
    Conte, D
    Guadagnino, V
    Pazienza, V
    Festi, D
    Spirito, F
    Andriulli, A
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (03) : 292 - 299
  • [38] Anemia associated with pegylated interferon-α2a and α2b therapy in hemodialysis patients
    Espinosa, M.
    Arenas, M. D.
    Aumente, M. D.
    Barril, G.
    Buades, J. M.
    Aviles, B.
    Carretero, D.
    Alvarez-Lara, M. A.
    Carnicer, F.
    Martin-Malo, A.
    Ajama, P.
    CLINICAL NEPHROLOGY, 2007, 67 (06) : 366 - 373
  • [39] The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients
    Dogan, Umit B.
    Golge, Necmettin
    Akin, Mustafa S.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (11) : 1312 - 1316
  • [40] Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients
    Saleh, Mohammad I.
    CLINICAL PHARMACOKINETICS, 2017, 56 (11) : 1369 - 1379
12345